Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.
The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.
Cocrystal Pharma (COCP) filed an 8-K stating it announced receipt of a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). The announcement was made on October 27, 2025.
The company furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is not incorporated by reference into other filings. Cocrystal’s common stock trades on the Nasdaq Capital Market under the symbol COCP.
Cocrystal Pharma, Inc. filed an S-1 registration statement to register shares held by selling stockholders under the Nasdaq symbol COCP. The prospectus states the selling stockholders may sell their shares at fixed, market-related or negotiated prices through various methods, and the company will not receive proceeds from those sales except to the extent of any cash exercises of the Warrants. The filing references standard risk disclosures warning that purchasers may lose their entire investment. Named selling stockholders include Orca Capital AG and L1 Capital Global Opportunities Master Fund, Ltd. The filing also lists estimated offering-related fees: legal $10,000, accounting $5,000 and a total of $15,702.38. The document includes officer and director signatures.
Cocrystal Pharma, Inc. filed an S-1 registration statement to register shares held by selling stockholders under the Nasdaq symbol COCP. The prospectus states the selling stockholders may sell their shares at fixed, market-related or negotiated prices through various methods, and the company will not receive proceeds from those sales except to the extent of any cash exercises of the Warrants. The filing references standard risk disclosures warning that purchasers may lose their entire investment. Named selling stockholders include Orca Capital AG and L1 Capital Global Opportunities Master Fund, Ltd. The filing also lists estimated offering-related fees: legal $10,000, accounting $5,000 and a total of $15,702.38. The document includes officer and director signatures.
Cocrystal Pharma, Inc. entered into a securities purchase agreement for a registered direct stock offering and concurrent private placement of warrants. The company agreed to sell 2,764,710 common shares at $1.70 per share and issue Investor Warrants to purchase up to 5,529,420 additional shares at an initial exercise price of $1.50 per share. The transaction closed with gross proceeds of approximately $4.75 million before fees, with net proceeds intended for general corporate purposes and development of antiviral medicines. Investor Warrants are exercisable immediately, subject to 4.99% or, at the holder’s election, 9.99% beneficial ownership limits, and expire 24 months after effectiveness of a resale registration statement the company must file by October 10, 2025.
Cocrystal Pharma, Inc. (COCP) is a clinical-stage antiviral biopharmaceutical company developing candidates for influenza, norovirus, coronavirus and HCV. The company reported a six-month net loss of $4.36 million and used $5.09 million of cash in operations through June 30, 2025. Cash and restricted cash totaled $4.84 million, total assets were $8.51 million and stockholders' equity was $5.33 million as of June 30, 2025. The company recorded a large accumulated deficit of $337.8 million (in thousands).
The filing discloses substantial doubt about the company’s ability to continue as a going concern and states current resources are not expected to be sufficient to fund operations beyond the next 12 months without additional financing. Clinical updates show MHRA authorization and ongoing analysis for the CC-42344 Phase 2a human challenge study and Phase 1 data for CDI-988 with safety/tolerability reported up to 1,200 mg. The company continues to rely on equity offerings and its ATM program for liquidity.
Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended June 30, 2025. On August 14, 2025, the company issued a press release detailing its results of operations and financial condition, which is furnished as Exhibit 99.1 to this report. The company notes that this information is furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities filings.